Gilead.com
Title
Gilead -- Discovering, Developing and Commercializing Therapeutics to Advance Patient Care
Description
Gilead Sciences, Inc. is a biopharmaceutical company that researches, develops and commercializes medication against life threatening diseases such as HIV/AIDS, respiratory diseases like cystic fibrosis and influenza, chronic hepatitis and cardiopulmonary conditions like resistant hypertension or pulmonary arterial hypertension.
Life Savings Drugs
The list of Gilead’s innovative drugs against life threatening diseases includes the oral treatment Letairis (ambrisentan) against pulmonary arterial hypertension, Atripla, the once-daily tablet treatment against HIV and Tamiflu (oseltamivir), a treatment researched and developed by Gilead scientist to fight influenza.
The products that are researched, developed and commercialized by Gilead Sciences can be divided into several different categories: HIV/AIDS medication like Atripla, Viread, Truvada and Emtriva, medication for cardiopulmonary and respiratory conditions like Letairis, Tamiflu and Flolan, the Hepsera treatment for chronic hepatitis and innovative medication for other conditions like “wet” AMD or systemic fungal infections in adults.
Curing AIDS
Among the most successful of the company’s drugs there are Letairis, Truvada, Atripla and Emtriva and Gilead Sciences is well known for its battle against HIV/AIDS. Emtriva (emtricitabine) and Viread (tenofovir disoproxil fumarate) are among the first drugs against HIV/AIDS developed by Gilead Sciences. They are both nucleoside reverse transcriptase inhibitors (NRTI) in the form of once-daily oral medication, thus simplifying the treatment of HIV/AIDS for adults. Both Emtriva and Viread must be combined with other retroviral agents. The next treatment, approved in 2004 in the U.S. and in 2005 in the E.U. is a combination of the previous two called Truvada. The Truvada pill contains both Viread as well as Emtriva and is a once-daily oral treatment that must be combined with other antiretroviral agents. The latest HIV/AIDS treatment researched and developed by Gilead Sciences is Atripla, a combination of Truvada and Sustiva (efavirenz) approved in the U.S. in 2006. This is the first and so far the only once a day tablet that fights HIV infections in adults without the assistance of other antiretroviral agents.
Hepatitis B Cure from Gilead and Others
For the treatment of chronic hepatitis B Gilead scientists have come up with Hepsera (adefovir dipivoxil), an oral nucleoside reverse transcriptase inhibitor (NRTI) to be used once every day. The medication met with the approval; of the U.S. government in 2002 and that of the E.U. in 2003. Flolan is an epoprostenol sodium injection developed by GlaxoSmithKline and commercialized by Gilead in the U.S. The injection is used in the intravenous treatment of pulmonary hypertension. Tamiflu (oseltamivir phosphate) was developed by Gilead Sciences as a neuraminidase inhibitor pill to be used in the treatment as well as the prevention of influenza A and B.
The most recent medication to be used in the treatment of pulmonary arterial hypertension that was developed by Gilead is Letairis (ambrisentan). This is an endothelin receptor antagonist to be used once every day for the delay of clinical worsening and the improvement of exercise capacity. The treatment was approved in the U.S. in 2007.
Other medication developed by Gilead Sciences includes Vistide, an injection used to treat cytomegalovirus retinitis in patients with AIDS, AmBisome, an injection used in the treatment of systemic fungal infections and Macugen, an injection used in the treatment of eye diseases like AMD (age-related macular degeneration).
Research Plans
Aside from the drugs already commercialized globally, Gilead Sciences continues to research and develop medication that could be used in the advanced treatment of life threatening diseases like cystic fibrosis, hepatitis C, HIV/AIDS and even certain types of cancer.
There are two new drugs in Phase III clinical trials at the moment: Darusentan and Aztreonam lysine for inhalation. Darusentan is an endothelin receptor antagonist and is being tested as a possible treatment for resistant hypertension and Aztreonam lysine for inhalation is used in an attempt to control the symptoms of cystic fibrosis and prevent further lung damage in patients with CF. In its continued battle against HIV/AIDS Gilead is now testing an integrated inhibitor called Elvitegravir, a new kind of antiretroviral drug needed for patients who have developed resistance to the HIV medication already available.
Medication to be used in the treatment of hepatitis C infections (GS 9190) and in the treatment of certain types of cancer (GS 9219) will enter Phase I clinical trials by the end of the current year. Founded twenty years ago in California, Gilead Sciences is well known around the world for its continued struggle against life threatening diseases such as HIV/AIDS, cardiopulmonary and respiratory conditions, hepatitis B and C and even certain types of cancer.
Languages
English
Address
- 333 Lakeside Dr
- Foster City CA 94404 US
Logos
Additional Information
- http://www.gilead.com
- http://www.wikipedia.org/wiki/Gilead_Sciences
- http://www.businessweek.com
- http://www.boston.com/business/healthcare/articles/2007/07/20/ahead_of_the_bell_gilead_sciences
Related Domains
External Links
- Stock: GILD
- Alexa: Gilead.com
